UY25877A1 - Antígenos estreptococo - Google Patents

Antígenos estreptococo

Info

Publication number
UY25877A1
UY25877A1 UY25877A UY25877A UY25877A1 UY 25877 A1 UY25877 A1 UY 25877A1 UY 25877 A UY25877 A UY 25877A UY 25877 A UY25877 A UY 25877A UY 25877 A1 UY25877 A1 UY 25877A1
Authority
UY
Uruguay
Prior art keywords
polypeptide
streptococcal
infection
proteins
useful
Prior art date
Application number
UY25877A
Other languages
English (en)
Inventor
Clement Rioux
Isabelle Pineau
Bernard R Brodeur
Josee Hamel
Denis Martin
Nathalie Charland
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25877(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of UY25877A1 publication Critical patent/UY25877A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Proteínas de estreptococos y polinucleótidos que las codifican; donde dicha proteínas son antigénicas y por lo tanto son componentes de vacunas útiles para la profilaxis o terapia de la infección de estreptococos en mamíferos. Se incluye un método para producir un polipéptido que comprende cultivar una célula huésped transfectada con un vector que comprende un polipéptido donde el ADN está unido en forma operativa a la región de control de expresión, bajo la condiciones adecuadas para la expresión de dicho polipéptido; como también se incluyen métodos recombinantes para producir los antígenos proteicos así como ensayos de diagnostico para detectar infección bacteriana por estreptococos. Una composición de vacuna que comprende un polipéptido según lo descrito y un vehículo, diluyente o adyuvante farmacéuticamente aceptable es útil para el tratamiento terapéutico o profiláctico de la meningitis, otitis media y bacteriemia o infección de neumonía.
UY25877A 1998-12-23 1999-12-23 Antígenos estreptococo UY25877A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11380098P 1998-12-23 1998-12-23

Publications (1)

Publication Number Publication Date
UY25877A1 true UY25877A1 (es) 2000-08-21

Family

ID=22351610

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25877A UY25877A1 (es) 1998-12-23 1999-12-23 Antígenos estreptococo

Country Status (30)

Country Link
EP (2) EP1141306B1 (es)
JP (2) JP4761623B2 (es)
KR (4) KR101078919B1 (es)
CN (3) CN1191362C (es)
AP (1) AP2001002199A0 (es)
AR (1) AR029322A1 (es)
AT (1) ATE394489T1 (es)
AU (1) AU1764900A (es)
BR (1) BR9916477A (es)
CA (1) CA2356836C (es)
CL (1) CL2009002037A1 (es)
CY (3) CY1108223T1 (es)
CZ (2) CZ302790B6 (es)
DE (1) DE69938670D1 (es)
DK (3) DK2261358T3 (es)
EA (1) EA007409B1 (es)
ES (3) ES2400280T3 (es)
HK (1) HK1118575A1 (es)
HU (1) HU229664B1 (es)
IL (3) IL143905A0 (es)
MX (1) MXPA01006427A (es)
NO (1) NO330800B1 (es)
NZ (1) NZ512574A (es)
OA (1) OA11736A (es)
PL (3) PL206576B1 (es)
PT (3) PT1141306E (es)
TR (2) TR200102497T2 (es)
UY (1) UY25877A1 (es)
WO (1) WO2000039299A2 (es)
ZA (1) ZA200105114B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757697A3 (en) 1998-02-20 2007-05-30 ID Biomedical Corporation Group B streptococcus antigens
US20030134407A1 (en) 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
EP1801218A3 (en) * 1998-07-27 2007-10-10 Sanofi Pasteur Limited Nucleic acids and proteins from streptococcus pneumoniae
JP4689044B2 (ja) 1998-12-21 2011-05-25 メディミューン，インコーポレーテッド ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
ES2400280T3 (es) * 1998-12-23 2013-04-08 Id Biomedical Corporation Of Quebec Antígenos de estreptococos
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
ES2316450T3 (es) 2000-06-12 2009-04-16 University Of Saskatchewan Proteina gapc quimerica de streptococcus y su uso en vacunacion y diagnostico.
US6866855B2 (en) 2000-06-12 2005-03-15 University Of Saskatchewan Immunization of dairy cattle with GapC protein against Streptococcus infection
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
EP2281891A3 (en) 2000-06-20 2011-08-17 ID Biomedical Corporation Streptococcus antigens
WO2002079475A2 (en) * 2001-03-30 2002-10-10 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
CA2453062C (en) 2001-07-06 2013-04-02 Shire Biochem Inc. Group b streptococcus bvh-a5 antigens and corresponding dna fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens
WO2004078907A2 (en) * 2003-03-04 2004-09-16 Intercell Ag Streptococcus pyogenes antigens
EP2333114A1 (en) * 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigens
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US20090010959A1 (en) 2005-12-22 2009-01-08 Ralph Leon Biemans Pneumococcal Polysaccharide Conjugate Vaccine
BRPI0813307C1 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, processo para fabricar a vacina
AU2008280799B2 (en) * 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
AU2009237647A1 (en) 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
US20100092526A1 (en) 2008-09-26 2010-04-15 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
BRPI1014494A2 (pt) 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
NZ620441A (en) 2009-09-03 2015-08-28 Pfizer Vaccines Llc Pcsk9 vaccine
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
US9944680B2 (en) 2010-12-03 2018-04-17 Sandfi Pasteur Limited Composition for immunization against Streptococcus pneumoniae
WO2012100234A1 (en) 2011-01-20 2012-07-26 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
JP2014515035A (ja) 2011-05-17 2014-06-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ストレプトコッカス・ニューモニエに対するワクチン
SG11201403877PA (en) * 2012-01-05 2014-09-26 Deutsches Krebsforsch Means and methods for treating or diagnosing idh1 r132h mutant-positive cancers
EP2931743A4 (en) * 2012-12-14 2016-08-03 Sanofi Pasteur Ltd METHOD FOR ASSESSING IMMUNOGENICITY
PL3096783T3 (pl) 2014-01-21 2021-12-13 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
SG11201604728XA (en) 2014-01-21 2016-08-30 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR102049825B1 (ko) 2014-01-21 2019-12-03 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
WO2015121783A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
MX2017009308A (es) 2015-01-15 2017-11-08 Pfizer Composiciones inmunogenicas para usar en vacunas neumococicas.
PE20180657A1 (es) 2015-07-21 2018-04-17 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
HRP20220573T1 (hr) 2017-01-20 2022-06-10 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
JP2022542316A (ja) 2019-07-31 2022-09-30 サノフィ パスツール インコーポレイテッド 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物およびその使用方法
CN114667343A (zh) 2019-11-01 2022-06-24 辉瑞大药厂 大肠杆菌组合物及其方法
CN115362177A (zh) 2020-02-21 2022-11-18 辉瑞公司 糖类的纯化
CA3173729A1 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
CA3199610A1 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3200602A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4333879A1 (en) 2021-05-03 2024-03-13 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
AU2022281543A1 (en) 2021-05-28 2023-11-23 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
EP0656014B1 (en) * 1993-03-19 2003-05-14 LINDAHL, Gunnar Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition
EP0832238A1 (en) * 1995-06-07 1998-04-01 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
US5928895A (en) * 1996-09-24 1999-07-27 Smithkline Beecham Corporation IgA Fc binding protein
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
WO1998018930A2 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
CA2305016A1 (en) * 1997-09-24 1999-04-01 Regents Of The University Of Minnesota Human complement c3-degrading proteinase from streptococcus pneumoniae
WO1999053940A1 (en) * 1998-04-23 1999-10-28 Uab Research Foundation PNEUMOCOCCAL SURFACE PROTEIN C(PspC), EPITOPIC REGIONS AND STRAIN SELECTION THEREOF, AND USES THEREFOR
WO2000006737A2 (en) * 1998-07-27 2000-02-10 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
CN1318103A (zh) * 1998-07-27 2001-10-17 微生物技术有限公司 肺炎链球菌的核酸和蛋白质
EP1115875A1 (en) * 1998-09-24 2001-07-18 Regents Of The University Of Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
JP4689044B2 (ja) * 1998-12-21 2011-05-25 メディミューン，インコーポレーテッド ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
ES2400280T3 (es) * 1998-12-23 2013-04-08 Id Biomedical Corporation Of Quebec Antígenos de estreptococos

Also Published As

Publication number Publication date
KR20080036666A (ko) 2008-04-28
IL194230A0 (en) 2011-08-01
ZA200105114B (en) 2002-11-21
CL2009002037A1 (es) 2010-06-25
KR20010104693A (ko) 2001-11-26
ES2480417T3 (es) 2014-07-28
CN100398653C (zh) 2008-07-02
JP4761623B2 (ja) 2011-08-31
PT1950302E (pt) 2013-01-16
AU1764900A (en) 2000-07-31
CY1108223T1 (el) 2014-02-12
KR101078919B1 (ko) 2011-11-01
EP1141306A2 (en) 2001-10-10
NO20013045D0 (no) 2001-06-19
EP2261358A2 (en) 2010-12-15
PL349777A1 (en) 2002-09-09
CA2356836A1 (en) 2000-07-06
BR9916477A (pt) 2004-06-22
EA007409B1 (ru) 2006-10-27
DK2261358T3 (da) 2014-07-28
NO20013045L (no) 2001-08-20
IL143905A (en) 2011-05-31
EP1141306B1 (en) 2008-05-07
KR100802198B1 (ko) 2008-02-11
EP2261358A3 (en) 2011-02-23
CZ302790B6 (cs) 2011-11-09
ES2400280T3 (es) 2013-04-08
JP2002533123A (ja) 2002-10-08
TR200200633T2 (tr) 2002-06-21
DE69938670D1 (de) 2008-06-19
NZ512574A (en) 2004-03-26
OA11736A (en) 2005-06-12
CN1332803A (zh) 2002-01-23
WO2000039299A3 (en) 2000-11-02
TR200102497T2 (tr) 2002-01-21
PT2261358E (pt) 2014-07-30
PT1141306E (pt) 2008-07-30
CZ303675B6 (cs) 2013-02-27
PL205041B1 (pl) 2010-03-31
DK1141306T3 (da) 2008-08-18
MXPA01006427A (es) 2002-06-04
CN101134775A (zh) 2008-03-05
CN1654657A (zh) 2005-08-17
HK1118575A1 (en) 2009-02-13
KR101170203B1 (ko) 2012-07-31
ATE394489T1 (de) 2008-05-15
EP2261358B1 (en) 2014-05-14
ES2306528T3 (es) 2008-11-01
IL194230A (en) 2013-12-31
AR029322A1 (es) 2003-06-25
DK1950302T3 (da) 2013-01-14
HUP0104774A3 (en) 2007-10-29
WO2000039299A2 (en) 2000-07-06
NO330800B1 (no) 2011-07-18
HU229664B1 (en) 2014-04-28
CZ20012161A3 (cs) 2001-10-17
CA2356836C (en) 2011-09-13
JP2010142246A (ja) 2010-07-01
CY1115340T1 (el) 2017-01-04
EA200100565A1 (ru) 2002-04-25
HUP0104774A2 (hu) 2002-04-29
JP5039802B2 (ja) 2012-10-03
IL143905A0 (en) 2002-04-21
AP2001002199A0 (en) 2001-09-30
CN1191362C (zh) 2005-03-02
CY1114722T1 (el) 2016-10-05
KR20100063814A (ko) 2010-06-11
PL206576B1 (pl) 2010-08-31
KR20060134227A (ko) 2006-12-27
PL204073B1 (pl) 2009-12-31
KR100891398B1 (ko) 2009-04-02

Similar Documents

Publication Publication Date Title
UY25877A1 (es) Antígenos estreptococo
ATE348887T1 (de) Streptococcus pneumoniae antigene und impfstoffe
CN113365656A (zh) 用于非洲猪瘟病毒的免疫原性组合物
AR033980A1 (es) Antigeno de estreptococos
NO20004161L (no) Gruppe B streptokoccus antigener
BR0015137A (pt) Peptìdeos antigênicos de neisseria
DE69942810D1 (de) Modifizierter Hitzeschockprotein-Antigenpeptid-Komplex
JP2009542196A (ja) 小型の化膿連鎖球菌抗原およびそれらの使用
NO883763L (no) Terapeutiske blandinger mot streptokokkinfeksjoner, transformerte verter, fremgangsmaater ved immunisering og genespleisingsprodukter.
NO971768L (no) Hemoglobinreseptorer fra Neisseriae
DE3752131D1 (de) Impfstoffe und diagnosetest für haemophilus influenzae
Rössler et al. Molecular and immunological characterization of the p83/100 protein of various Borrelia burgdorferi sensu lato strains
ATE109512T1 (de) Expression und diagnose mit gag-kodierten peptiden, die mit antikörpern gegen lav immunologisch reaktiv sind.
HUT52819A (en) Process for producing polypeptides suitable for diagnosing mycoplasmic contamination of swine, by way of recombinant dna technique
Singh et al. Molecular characterization and computational analysis of the major outer membrane protein (ompH) gene of Pasteurella multocida P52
DE68923286D1 (de) Impfstoffe und testsätze für haemophilus influenzae.
CA2475821A1 (en) Group b streptococcus antigens
ES2377569T3 (es) Polinucleótidos de Haemophilus parasuis y su uso
Mendes et al. General characterization of Tityus fasciolatus scorpion venom. Molecular identification of toxins and localization of linear B-cell epitopes
CA2438921A1 (en) Streptococcus pyogenes polypeptides and corresponding dna fragments
JP2004531235A5 (es)
RU2019189C1 (ru) Способ получения видоспецифичных эймерийных антигенов
CA2432525A1 (en) Streptococcus pyogenes antigens and corresponding dna fragments
Johnson Characterization of group A streptococcal R-28 antigen purified by hydroxyapatite column chromatography
Kabeya et al. Cloning and expression of Bartonella henselae sucB gene encoding an immunogenic dihydrolipoamide succinyltransferase homologous protein

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20090414